dpp 4 inhibitor and glp 1 agonist Clinical Use of DPP-4 Inhibitors GLP-1-RA and DPP-4 inhibitors in

Both GIPR and GLP-1R are expressed in overlapping brain regions including the ARC, PVN, and AP

The more prolonged exposure to the long-acting analogues is associated with less prandial glycaemic efficacy but greater insulin secretion and thus lower blood glucose concentrations during the post-absorptive period

Semaglutide GLP-1 injections should only be used by patients who have been prescribed the medication by a qualified physician

Their primary indication is the management of type 2 diabetes, where they are used alongside diet and exercise to improve glycaemic control by enhancing insulin secretion, suppressing glucagon, and supporting healthier glucose regulation 3 , 4

The FDA states that exenatide, the first GLP-1 receptor agonist, is being phased out as of January 2025 due to a GLP-1 scarcity